· via TechCrunch
Isomorphic Labs raises $5B Series C to move AI-designed drugs into clinical trials
The DeepMind spinout Isomorphic Labs has raised $5 billion in a Series C round to push its AI-designed drug candidates into clinical trials, with Greenoaks, Sequoia and Andreessen Horowitz among the backers.

Isomorphic Labs, the drug-discovery company spun out of Google's DeepMind in 2021, has raised $5 billion in a Series C round as it prepares to move its AI-designed drug candidates into clinical trials, according to TechCrunch.
The round
The financing was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining as a new investor alongside others. TechCrunch reports that all of Isomorphic's existing backers also returned, including Alphabet's venture arms GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund.
Isomorphic did not disclose the valuation attached to the round. Bloomberg had reported earlier in November that the company was looking to raise at a valuation of roughly $50 billion, but that figure has not been confirmed.
From AlphaFold to drug design
Isomorphic's work is a direct descendant of AlphaFold, the DeepMind system that predicts the three-dimensional structure of proteins using nothing more than their genetic sequence. That research earned the company's founder and CEO, Demis Hassabis, together with DeepMind's John Jumper, the Nobel Prize in Chemistry.
On top of that foundation, Isomorphic has built what it describes as a drug-design engine: a collection of simulation AI models that explore different areas of chemistry to help design new medicines. According to TechCrunch, the company says the programme has delivered positive preclinical results in oncology and immunology. It has also struck deals with major pharmaceutical companies, including Eli Lilly, Novartis and Johnson & Johnson.
A first raise after a leadership shift
The Series C is Isomorphic's first fundraise since Hassabis stepped down as head of DeepMind to concentrate on drug discovery, a move that also saw him take on a chairman role at the AI lab. The new money arrives just months after a $2.1 billion Series B closed in May, making 2026 an unusually capital-intensive year for the spinout.
TechCrunch reports that the fresh capital will fund continued development of the drug-design engine and support an expansion into additional types of medicine.
Why it matters
The size of the round, coming on top of $2.1 billion raised since May, marks a turning point for AI-driven drug discovery. Companies in this space have so far mostly demonstrated their value through partnerships and preclinical milestones; running clinical trials is a far more expensive proposition, and one where most experimental drugs historically fail.
If Isomorphic's candidates hold up once tested in humans, it strengthens the argument that simulation and AI-driven design can compress one of the costliest pipelines in science. If they do not, the gap between computational prediction and biological reality becomes the central problem for the entire field. Either way, with Demis Hassabis now dedicated to the effort full-time and more than $7 billion raised since May, Isomorphic has the resources to find out.
- #ai
- #drug-discovery
- #biotech
- #funding
- #deepmind